News
JNJ
149.27
-0.43%
-0.65
Pharma R&D productivity seen improving for the first time in years - Deloitte
Healthcare Pharma R&D productivity seen improving for the first time in years - Deloitte. A new report from Deloite says productivity appears to have turned a corner in 2023. The internal rate of return from biopharma companies has been in decline since 2010.
Seeking Alpha · 6h ago
5 Relatively Secure And Cheap Dividend Stocks To Invest In - May 2024
5 Relatively Secure And Cheap Dividend Stocks To Invest In - May 2024. Five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We select five conservative DGI stocks from more than 7,500 companies traded on U.S. Exchanges. The primary list yields about 3.7%.
Seeking Alpha · 13h ago
New Prostate Cancer Treatment Data Not Much Help to Johnson & Johnson (NYSE:JNJ)
TipRanks · 1d ago
J&J releases new Erleada data buoying benefit of prostate cancer treatment
J&J releases new Erleada data buoying benefit of prostate cancer treatment. New phase 2 data showed no increase in prostate-specific antigen levels in the blood at 24 months. Patients given a combination of Johnson & Johnson's ErleADA and androgen deprivation therapy.
Seeking Alpha · 1d ago
Johnson & Johnson Announces Phase 2 Data For ERLEADA Plus Androgen Deprivation Therapy Following Radical Prostatectomy In Patients With High-Risk Localized Prostate Cancer Show 100% Biochemical Free Recurrence Rate More Than Two Years Post-Surgery; Study Met Its Primary Endpoint; Safety Profile Of ERLEADA With ADT Was Consistent With Previous Reports
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer experience disease recurrence within two years of surgery. Results from the Apa-RP study show 100% biochemical recurrence-free rate at 24 months in patients with radical prostatectomy. Results presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Study evaluated adjuvant treatment with ERLEADA® and androgen deprivation therapy.
Benzinga · 1d ago
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
NASDAQ · 1d ago
Johnson & Johnson Says TAR-200 Monotherapy Shows Greater Than 80% Complete Response Rate In Patients With High-Risk Non-Muscle-Invasive Bladder Cancer; New Data From Phase 2b Sunrise-1 Study Show Rapid Achievement Of Complete Response With 98% Achieving A CR Within 12 Weeks
Benzinga · 1d ago
Kenvue Q1 Earnings Preview: A Potentially Troubling Trend
Kenvue Inc. Separated from healthcare giant Johnson & Johnson almost a year ago. The company will release its first quarter 2024 earnings report on Tuesday, May 7. Kenvue is expected to report a -11% decline in full-year 2024 EPS. I discuss the main reason for the comparatively cheap valuation of KVUE stock.
Seeking Alpha · 1d ago
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
NASDAQ · 1d ago
Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24
Johnson & Johnson will be paying its dividend of $1.24 on the 4th of June. The company has increased its dividend to 3.3%. The last dividend was easily covered by the company's earnings. Johnson & Johnson has a solid track record of growing its dividends at a steady rate. But there are two warning signs for investors to be aware of.
Simply Wall St · 1d ago
3 Dividend Growth Stocks that Just Raised Their Payouts
Three companies that recently raised their payouts are Johnson & Johnson, Southern Company and TJX Companies. One of these stocks boosted its payouts by as much as 13%. Dividend increases can be a good sign a company is doing well. TJX companies and Southern Company are good dividend stocks to buy right now.
The Motley Fool · 1d ago
5 Expected Dividend Increases In May 2024
5 Expected Dividend Increases in May 2024 for Cardinal Health, Lowe's Companies, Medtronic, Chubb Limited, and LyondellBasell Industries. Two Big Tech companies, Apple and Google, announced dividend increases in the last month. The featured stocks have a history of announcing their annual increases in May.
Seeking Alpha · 1d ago
Tracking Yacktman Asset Management Portfolio - Q1 2024 Update
Yacktman Asset Management's 13F portfolio value increased from $10.75B to $11.12B this quarter. Largest holding in the portfolio is Canadian Natural Resources at 10.32%. New stakes include Kellanova and Darling Ingredients, while stake disposals include Weatherford International.
Seeking Alpha · 1d ago
Is Merck Stock Fully Valued At $130?
NASDAQ · 2d ago
Should You Pick Bristol Myers Squibb Stock At $45?
NASDAQ · 2d ago
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
Major index futures point to a positive open on Thursday. U.S. Stocks closed mixed on Wednesday after the Federal Reserve's rate decision. Apple, Inc. Is due to report after the market closes. Jobless claims and bond yields are due to be released later in the day.
Benzinga · 2d ago
Johnson & Johnson’s Strategic Settlement Plan for Ovarian Cancer Talc Claims: Financial Implications and Outlook
TipRanks · 2d ago
Hold Rating on Johnson & Johnson Amid Ongoing Talc Litigation Uncertainties and Settlement Efforts
TipRanks · 2d ago
BeiGene, AbbVie patent spat to get trial from USPTO appeals board
Healthcare BeiGene, AbbVie patent spat to get trial from USPTO appeals board. Pharmacyclics has accused BeiGene's Brukinsa of violating a patent belonging to Imbruvica. Both are BTK inhibitors approved to treat leukemia and lymphoma.
Seeking Alpha · 3d ago
Dow rallies nearly 325 points on gains for Johnson & Johnson, Amazon.com Inc. shares
MarketWatch · 3d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.